File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment-related death during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A meta-analysis of randomized studies

TitleTreatment-related death during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A meta-analysis of randomized studies
Authors
Issue Date2016
Citation
PLoS ONE, 2016, v. 11, n. 6, article no. e0157455 How to Cite?
Abstract© 2016 Zhao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Treatment related death (TRD) is the worst adverse event in chemotherapy and radiotherapy for patients with cancer, the reports for TRDs were sporadically. We aimed to study TRDs in non-small cell lung cancer (NSCLC) patients treated with concurrent chemoradiotherapy (CCRT), and determine whether high radiation dose and newer chemotherapy regimens were associated with the risk of TRD. Data from randomized clinical trials for locally advanced/unresectable NSCLC patients were analyzed. Eligible studies had to have at least one arm with CCRT. The primary endpoint was TRD. Pooled odds ratios (ORs) for TRDs were calculated. In this study, a total of fifty-three trials (8940 patients) were eligible. The pooled TRD rate (accounting for heterogeneity) was 1.44% for all patients. In 20 trials in which comparison of TRDs between CCRT and non-CCRT was possible, the OR (95% CI) of TRDs was 1.08 (0.70-1.66) (P = 0.71). Patients treated with third-generation chemotherapy and concurrent radiotherapy had an increase of TRDs compared to those with other regimens in CCRT (2.70% vs. 1.37%, OR = 1.50, 95% CI: 1.09-2.07, P = 0.008). No significant difference was found in TRDs between high (≥ 66 Gy) and low (< 66 Gy) radiation dose during CCRT (P = 0.605). Neither consolidation (P = 0.476) nor induction chemotherapy (P = 0.175) had significant effects with increased TRDs in this study. We concluded that CCRT is not significantly associated with the risk of TRD compared to non-CCRT. The third-generation chemotherapy regimens may be a risk factor with higher TRDs in CCRT, while high dose radiation is not significantly associated with more TRDs. This observation deserves further study.
Persistent Identifierhttp://hdl.handle.net/10722/267044
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorZhao, Jing-
dc.contributor.authorXia, Yingfeng-
dc.contributor.authorKaminski, Joseph-
dc.contributor.authorHao, Zhonglin-
dc.contributor.authorMott, Frank-
dc.contributor.authorCampbell, Jeff-
dc.contributor.authorSadek, Ramses-
dc.contributor.authorKong, Feng Ming-
dc.date.accessioned2019-01-31T07:20:21Z-
dc.date.available2019-01-31T07:20:21Z-
dc.date.issued2016-
dc.identifier.citationPLoS ONE, 2016, v. 11, n. 6, article no. e0157455-
dc.identifier.urihttp://hdl.handle.net/10722/267044-
dc.description.abstract© 2016 Zhao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Treatment related death (TRD) is the worst adverse event in chemotherapy and radiotherapy for patients with cancer, the reports for TRDs were sporadically. We aimed to study TRDs in non-small cell lung cancer (NSCLC) patients treated with concurrent chemoradiotherapy (CCRT), and determine whether high radiation dose and newer chemotherapy regimens were associated with the risk of TRD. Data from randomized clinical trials for locally advanced/unresectable NSCLC patients were analyzed. Eligible studies had to have at least one arm with CCRT. The primary endpoint was TRD. Pooled odds ratios (ORs) for TRDs were calculated. In this study, a total of fifty-three trials (8940 patients) were eligible. The pooled TRD rate (accounting for heterogeneity) was 1.44% for all patients. In 20 trials in which comparison of TRDs between CCRT and non-CCRT was possible, the OR (95% CI) of TRDs was 1.08 (0.70-1.66) (P = 0.71). Patients treated with third-generation chemotherapy and concurrent radiotherapy had an increase of TRDs compared to those with other regimens in CCRT (2.70% vs. 1.37%, OR = 1.50, 95% CI: 1.09-2.07, P = 0.008). No significant difference was found in TRDs between high (≥ 66 Gy) and low (< 66 Gy) radiation dose during CCRT (P = 0.605). Neither consolidation (P = 0.476) nor induction chemotherapy (P = 0.175) had significant effects with increased TRDs in this study. We concluded that CCRT is not significantly associated with the risk of TRD compared to non-CCRT. The third-generation chemotherapy regimens may be a risk factor with higher TRDs in CCRT, while high dose radiation is not significantly associated with more TRDs. This observation deserves further study.-
dc.languageeng-
dc.relation.ispartofPLoS ONE-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleTreatment-related death during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A meta-analysis of randomized studies-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1371/journal.pone.0157455-
dc.identifier.pmid27300551-
dc.identifier.scopuseid_2-s2.0-84976351543-
dc.identifier.volume11-
dc.identifier.issue6-
dc.identifier.spagearticle no. e0157455-
dc.identifier.epagearticle no. e0157455-
dc.identifier.eissn1932-6203-
dc.identifier.isiWOS:000377822200052-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats